2 Abstract Purpose: We tested the combination of a tumor lysate vaccine with a panel of costimulatory molecules to identify an immunotherapeutic approach capable of curing established murine gliomas.
Introduction
Glioblastoma multiforme (GBM) is a lethal brain tumor with a median survival of [15] [16] [17] [18] [19] months (1) . There is an urgent need for more targeted and effective therapies. Recent studies have shown vaccines to be a promising adjuvant therapy for GBM (reviewed in (2) ). Major challenges in the field include the immunologically specialized nature of the brain and the immune suppression documented in GBM patients (3) (4) (5) . Vaccines Prior studies have shown that it is possible to break anergy by delivering agonist antibodies or recombinant ligands that activate costimulatory receptors present on T cells (reviewed in (7)). Blockade of inhibitory checkpoints such as Cytotoxic TLymphocyte Antigen 4 (CLTA4) on T cells is another strategy that has gained attention. The recent FDA approval of ipilimumab (a CTLA4 antagonist) for the treatment of metastatic melanoma is a first in class success that has invigorated the field of immunotherapy (8) . However, ipilimumab is not specific to tumor-reactive T cells, resulting in severe and long-lasting adverse events in an appreciable fraction of patients (9) ; this has led some to challenge the rationale for its use (10) . Indeed, many questions remain unresolved about the optimal use of these novel immunomodulatory drugs. In the case of drugs that activate T cell costimulatory receptors, what are the relative potencies of agonist antibodies versus recombinant activating ligands? How should such drugs be combined with the standard of care chemotherapy or experimental vaccines? The details of combination therapy, such as dose, timing, and frequency of administration are important considerations that can be preliminarily addressed in preclinical models. Laying this basic foundation of knowledge will enable rational clinical trial design.
We previously characterized immunomodulatory proteins consisting of the C-terminus of the Fc portion of immunoglobulin fused to costimulatory ligands: CD80, GITRL, OX40L, or 4-1BBL (11) (12) (13) (14) . Comparative studies of an anti-OX40 agonist antibody with Fc-OX40L demonstrated Fc-OX40L was far more potent on a per molecule basis (13) , establishing the rationale to develop this class of Fc-ligand fusion proteins. In this prior work, varying the dose and frequency of each drug led to the development of optimized single-agent treatment regimens. These regimens were capable of triggering tumorreactive T cells and tumor regression in murine models of colon and renal cell carcinoma (11) (12) (13) (14) . Nonetheless, such single agent approaches rely on endogenous tumor-reactive T cells as targets, which may be too limiting, justifying the investigation of vaccines that increase the frequency of responder T cells. We previously demonstrated the efficacy of a tumor cell lysate /toll-like receptor (TLR) agonist vaccine to treat mice bearing intracranial gliomas. The vaccine consisting of tumor cell lysate and CpG, a TLR 9 agonist, cured 50% of glioma-bearing mice through a mechanism requiring CD4 and CD8 T cells (15) . However, when this tumor cell vaccine was prepared in standard tissue culture conditions (e.g., atmospheric 21% oxygen) and modeled at clinically scalable antigen doses, the efficacy of vaccination was abolished despite evidence of immune priming (16) . One goal of this study was to determine if additional costimulation was necessary to achieve efficacy following vaccination with lysate/CpG. To address this we screened a panel of Fc-ligand fusion proteins in combination with the tumor lysate/CpG vaccine and identified Fc-OX40L as the most potent, demonstrating both single agent activity and synergy with the CpG/lysate vaccine. The optimal frequency, timing, and combination of Fc-OX40L with vaccination were established in mice bearing implanted GL261 gliomas. The efficacy of the optimized regimen was generalizable to other vaccine adjuvants (PolyICLC, a TLR3 agonist), other tumor models (breast carcinoma), and effective in combination with the standard of care chemotherapy for GBM, temozolomide. Comparative studies in two glioma models revealed inflammatory gene expression signatures that were associated with response rates to Fc-OX40L as a single agent. Collectively, these studies provide a wealth of information that can be exploited when considering the design of clinical trials.
Research. 
Materials and Methods
Animal Models and Cell Lines. The culture conditions for GL261-Luc and EMT6 have been described elsewhere (15, 17) . All animals were maintained in a specific pathogen free facility in accordance with the University of Minnesota Institutional Animal Care and Use Committee (IACUC) guidelines. For the implanted glioma model, seven-week-old C57BL/6 (B6) mice were purchased from Jackson Laboratory. Gliomas were established by intracranial inoculation of 15,000 GL261-Luc cells in 1 μL of Hank's balanced salt solution (HBSS) (Gibco) to syngeneic B6 mice. Animals were anesthetized with a ketamine/xylazine cocktail (54.7 mg/mL ketamine and 9.26 mg/mL xylazine) prior to surgery. Cells were implanted into the right striatum at coordinates 2.5 mm lateral, 0.5 mm anterior from the bregma, and 3 mm ventral from the surface of the brain (15) . Cells were delivered over 5 minutes at a rate of 0.2 μL/min. Tumor implantation was confirmed by bioluminescence imaging 3 days following inoculation; animals received 100 μL Luciferin (Gold Biotechnology) by intraperitoneal (IP) injection and were imaged with an IVIS50 system (Caliper Life Sciences). The de novo glioma model was induced by transposon-mediated gene transfer, as we have previously described (18) . The following plasmids were injected into the brains of B6 mice at 1-2 days following birth, pT2/C-Luc//PGK-SB13 (0.07μg), pT/CAGGS-NRASV12 (0.14 μg), and pT2/shP53/GFP4/mPDGF (0.14 μg). Mice that became moribund where humanely Costimulatory Fusion Proteins Production and Delivery. Costimulatory fusion proteins were genetically engineered, biochemically characterized, and functionally validated as described previously (11) (12) (13) (14) . Previously published optimal doses for each were first perfused with PBS to flush the capillaries. The brains were removed and minced into very fine (< 1mm) pieces with a razor, passed through a 70 μm filter, and subjected to a two layer Percoll gradient (70% and 30%) and centrifuged at 800xg for 30 minutes. The lymphocyte interface was harvested by aspiration. Cells were counted using trypan blue dye exclusion and a hemocytometer. For these studies antibodies against CD3 (clone 17A2), CD4 (clone GK1.5), CD8 (clone 53-67) (ebioscience), and Ki67 (clone B56) (BD Pharminogen) were used for phenotypic analysis. Intracellular Statistical Analyses. Statistical comparisons for lymphocyte counts were made by a Mann-Whitney (non-parametric) test. Expression of immune-related genes was compared using a student's t test. Differences in animal survival were evaluated by log-rank test. Differences in mean cytokine secretion among groups was evaluated for significance by ANOVA followed by Dunnett's test for pairwise comparisons. All tests were performed with Prism 4 software (Graph Pad Software, Inc). P values <0.05 were considered statistically significant.
Results

Comparative Efficacy of Combination Vaccine with Costimulatory Ligands
The efficacy of vaccination with lysate/CpG was tested alone and in combination with Fc-ligand fusion proteins. Mice bearing GL261 gliomas were primed intradermally by three vaccinations (days 3, 7, and 10), followed by daily IP injection of Fc-ligand on days 17-21 following tumor challenge. The rationale for this timing was to first prime tumor-reactive T cells, then provide a sustained (five consecutive days) co-stimulatory signal. Vaccine alone or the combination of vaccine with CD80-Fc or Fc-4-1BBL did not enhance survival compared to saline controls (Fig. 1A-C) . The vaccine/Fc-GITRL combination resulted in a statistically significant, albeit incremental, increase in survival without long-term survivors (Fig. 1D) . The vaccine/Fc-OX40L combination resulted in a significant increase in survival and 50% long-term survivors (Fig. 1E) . Author Manuscript Published OnlineFirst on July 10, 2012; DOI: 10.1158/1078-0432.CCR-12-0990 S1A). In order to assay for immunological memory, long-term survivors and naïve controls were intracerebrally challenged with GL261 in the contralateral hemisphere relative to initial challenge. No additional treatment was administered. All cured mice rejected rechallenge within 8 days (Supplementary Fig. S1B ) and survived long-term, whereas all naïve animals succumbed to tumor burden (Fig. 1F ).
This initial screen was carried out using previously determined optimal doses of each Fc-ligand fusion protein (range 25-150 μg/dose). For a more direct comparison, the identical screen was repeated by administering the Fc-fusion proteins or an agonist OX40 antibody (OX86) at the same dose of 50 μg. Using this more equivalent dosing scheme, only mice treated with vaccine/Fc-OX40L survived long-term (data not shown), confirming our initial experiments and the superior potency of Fc-OX40L to OX86 that was reported previously in other tumor models (13) . The difference in therapeutic potency of these molecules was not due to inactivate preparations because they all had an equivalent ability to enhance IL-2 elaboration in primary splenocytes cultures stimulated with a CD3 agonist antibody (Supplementary Fig. S2A ). Furthermore, IFNγ production was enhanced upon stimulation with each of the reagents, except CD80-Fc (Supplementary Fig. S2B ). The unique ability of the vaccine/Fc-OX40L combination therapy to cause tumor regression and establish immunological memory warranted further mechanistic studies.
T cell response correlates with survival outcome
Research. In order to understand how the various Fc-ligands altered immune responses, animals were treated as described in Figure 1 and euthanized on day 25. This time point was four days following the final Fc-ligand injection and was chosen because it was when initial tumor regression was noted by BLI (Supplementary Fig. S1 ). Lymphocytes from the brain and brain draining lymph node (DLN) were quantified and assayed for tumoricidal function. There was a two-to-three fold increase in the total number of cells in the DLN of vaccine/Fc-OX40L-treated animals compared to all other groups except Fc-GIRTL/vaccine ( Fig. 2A) . The difference between the Fc-GIRTL/vaccine and vaccine/Fc-OX40L groups was not statistically significant (p = 0.15). However, only cells isolated from the DLN of vaccine/Fc-OX40L-treated animals had appreciable tumoricidal function in ex vivo CTL assays (Fig. 2B) . These experiments revealed quantitative and functional differences in lymphocytes in the DLN that correlated with outcome; Fc-GIRTL/vaccine followed by vaccine/Fc-OX40L had increasingly superior survival as shown in Fig. 1 , whereas tumoricidal function was unique to vaccine/Fc-
OX40L.
Flow cytometry analyses demonstrated that animals in the vaccine/Fc-OX40L group had an increase in the percentage of CD4 and CD8 T cells at the tumor site (Fig. 3A) .
However, when absolute numbers were analyzed only 3/5 mice treated with vaccine/Fc-OX40L had increased numbers of CD4 and CD8 T cells at the tumor site (Fig. 3A) .
Due to the high animal-to-animal variability, this difference was statistically insignificant, 
correlated with the long-term term survival rate of 50%. A more robust assay was Ki67 staining, a marker of proliferation. There was a significant increase in the frequency of CD4 and CD8 brain infiltrating T cells that were mitotically active in vaccine/Fc-OX40L-treated mice (Fig. 3B) . The significance of this finding is unclear, but it may represent an intrinsic difference in the proliferative competence of T cells, consistent with previous studies that demonstrated OX40 agonists can break T cell anergy in tumor models (19) .
All together, these experiments established a link between complete response rate, priming in the DLN, tumoricidal function, and tumor infiltration of T cells that was unique to the vaccine/Fc-OX40L combination therapy. Further studies were then undertaken to systematically dissect the contribution of Fc-OX40L and the vaccine and optimize combination therapies.
Determination of the optimal treatment strategy
The potency of Fc-OX40L as a single agent was examined in glioma-bearing animals.
We treated well-established tumors, beginning treatment on day 17. Impressively, Fc-OX40L was capable of extending survival of tumor-bearing animals and curing 20%
(1/5) (Fig. 4A, Regimen 1) . In a further attempt to optimize complete response rates, vaccination was given concurrently with Fc-OX40L on days 7, 10, and 13 followed by 5 daily doses of Fc-OX40L alone (days [15] [16] [17] [18] [19] . This was reproducibly the most potent treatment, with 70% cure rates (5/7) (Fig. 4B, Regimen 2) . Variations of this treatment were tested to determine the contribution of vaccine and Fc-OX40L. Fc-OX40L alone given early (days 7, 10, and 13) (Regimen 3) had a weak therapeutic effect unless given in combination with vaccine (Regimen 4) (Fig. 4A, B) . The efficacy of Fc-OX40L given (Fig. 4A, B) . We focused on the timing and frequency used in regimen 2 in subsequent studies due to the greatest therapeutic index of this regimen.
Contribution of vaccine components (antigen vs. adjuvant) with Fc-OX40L
The components of the vaccine/Fc-OX40L treatment were broken down to determine which is necessary for maximum effect. Lysate, CpG, or the combination "vaccine" had no effect on survival (Supplementary Fig. S3A ). Both lysate/Fc-OX40L and lysate/CpG/Fc-OX40L were able to significantly extend survival with 50-60% cure rates (Supplementary Fig. S3B ). Therefore, a TLR agonist is dispensable to achieve complete responses. However, the addition of a TLR agonist (PolyICLC or CpG) to the regimen was associated with a delay in the time of initial death of the first 20-40% of animals compared to lysate/Fc-OX40L (Supplementary Fig. S3B-C) . In clinical oncology, the closest analogy would be to describe the contribution of the TLR agonist as increasing progression-free survival. Additionally, a single animal in the lysate/Fc-OX40L treatment group that was determined to be a complete responder through BLI subsequently died due to tumor recurrence at day 158, a phenomenon never observed in the lysate/CpG/Fc-OX40L-treated animals (Supplementary Fig. S3B ). OX40L had no effect on survival (Supplementary Fig. S3B-C This was a robust finding in the GL261 glioma model and extended to other models; notably the vaccine/Fc-OX40L regimen was curative in 5/5 mice bearing established EMT6 breast carcinoma (Supplementary Fig. S4 ).
Complete responses using temozolomide combination therapy associated with secondary malignancies
TMZ is a DNA alkylating chemotherapy that is part of the current standard of care for GBM (20) . Any investigational treatment will likely be delivered in combination with TMZ in the clinic. For that reason we studied the compatibility of the two treatment strategies. We attempted to model a likely scenario in newly diagnosed GBM patients, (Fig. 5A) . The survival of glioma bearing mice was not significantly different between the TMZ/Fc-OX40L and vaccine/Fc-OX40L groups; yielding 20-40% long-term survivor rates (Fig. 5B) . Strikingly, the addition of TMZ to vaccine/Fc-OX40L resulted in 100% complete tumor regression by day 50 after GL261 challenge (Fig. 5B) . However, 80% of the mice cured by the TMZ/vaccine/Fc-OX40L combination developed lymphoid neoplasia involving multiple organs, killing 80% (4/5) with a latency of 82-378 days (depicted in Fig. 5B ). These animals had enlarged spleens, lymph nodes, and livers.
Microscopic examination revealed massive infiltration of these organs and variable involvement of other tissues (e.g., lungs, skeletal muscle, pancreas, kidneys) by neoplastic medium to large round cells with a high mitotic index (up to or exceeding 3-6 mitotic figures per high powered field, 40x objective). Immunohistochemistry of the liver revealed that the neoplastic cells were CD3 positive but B220 and Pax5 negative in 2 animals, consistent with T cell lymphosarcoma (Supplementary Fig. S5A ). In the other 2 animals, the neoplastic cells were variably CD3, B220 and Pax5 positive (Supplementary Fig. S5B ). Confocal microscopy confirmed that the CD3 and B220 positive cells in these animals comprised distinct cell populations, and this was interpreted to be lymphosarcoma involving both T-and B-cell lineages in these animals (Supplementary Fig. S5C ). Glioma progression was the cause of death in all other animals in this experiment with the exception of a single mouse in the TMZ/Fc-OX40L group that died with evidence of microscopic disease on day 170 (Fig. 5B) . In all other experiments glioma progression was also the cause of death, as documented by neurologic deterioration and histological analysis of treated brains, except for two mice in the lysate/Fc-OX40L group (Supplementary Fig S3B) that died of unknown causes (data not shown).
Analysis of single agent Fc-OX40L in transplanted and spontaneous glioma models
It remained unclear how generalizable these data were to autochthonous glioma models. We therefore investigated the efficacy of Fc-OX40L in a de novo glioma model that is induced by oncogene transfer into neonatal mice as previously described (18) .
Plasmids encoding three oncogenes and a firefly luciferase reporter were delivered intracerebrally to transform endogenous brain cells within 1-2 days of birth. Beginning at the time of weaning, animals were imaged to identify when tumor formation occurred.
For lack of an adequate cell line to use for lysate generation (equivalent to autologous as in the GL261 system), Fc-OX40L was administered as a single agent. Treatment began when tumor was first detected by BLI as depicted in Fig. 6A . Fc-OX40L monotherapy caused a statistically significant increase in survival, although this difference was incremental and there were no long-term survivors (Fig. 6B) . This finding was in contrast to Fc-OX40L monotherapy in the GL261 model, which consistently cured 20-25% of mice (even those bearing 17-day established tumors), prompting us to further investigate the microenvironment of both tumor systems.
Gene expression profiling has proven useful in identifying differences between tumors and has lead to the further classification of gliomas beyond the histological standards to a molecular subtype (24) . In an attempt to understand the molecular differences between the two glioma models, we conducted a quantitative RT-PCR analysis of 30 immune-related genes in brains from both glioma models and normal B6 mice. Relative to normal brain, both tumor models exhibited log-fold increases in CD11c expression, a DC marker, and arginase-1 (Fig. 6C) . The arginase enzyme is released by myeloid derived suppressor cells, locally depletes L-arginine, and consequently impairs T cell proliferation and survival (25) . Response to costimulation may be dependent on which costimulatory molecules are absent endogenously. Interestingly, OX40L was the only co-stimulatory ligand of those tested in our models that had lower expression in the tumor relative to the normal brain in either model. The GL261 and spontaneous models differed in several important ways. GL261 tumors exhibited a 15-fold increase in IFN-γ expression compared to the spontaneous model, and consistent with this expressed more PD1-L, which is induced by IFNγ (26) . In addition, CD3 (a T cell marker) was more highly expressed in the GL261 model, whereas the NK cell marker CD49b was more highly expressed in the spontaneous model (Fig. 6C) ; although these were not statistically different they were trending toward significance (CD49b p=0.071, CD3 p=0.088). 
Discussion
highlighting the need for more potent immunotherapy and the induction of memory cells.
Recombinant costimulatory ligand-Fc fusion proteins offer an attractive adjuvant to vaccine immunotherapy. To this end, the purpose of this study was to screen a panel of Fc-ligands using doses previously optimized in other tumor models (11) (12) (13) (14) . Fc-OX40L was clearly the most efficacious in the GL261 vaccination model. We are cautious to avoid over-interpreting these data; this does not mean that one Fc-ligand is universally better than the others, considering that the dose, timing in relation to vaccination, and biologic activity of each agent was not systematically optimized prior to the screen that identified Fc-OX40L as our lead candidate. It is likely that the efficacy of each drug could be significantly changed by altering the temporal relationship to TCR signaling following vaccination. Nonetheless, this study is the first head-to-head screen Fig. S6 ).
Consistent with a model of vaccination increasing tumor-reactive T cell frequency, vaccination combined with Fc-OX40L synergistically increased survival rates in the GL261 model relative to Fc-OX40L monotherapy. We speculate that an important effect of Fc-OX40L is rescuing T cell anergy, as shown by enhancing tumoricidal function (Fig. 2B) . This hypothesis is consistent with other reports that have studied the OX40/anergy axis in greater detail (19, 28) . In addition, Fc-OX40L has been shown to activate tumor vasculature and tumor-associated DCs, revealing the complexity of response to this drug (29) . A significant percentage of infiltrating T cells expressed the proliferation marker Ki67 in the vaccine/Fc-OX40L group, supporting the notion that this treatment yields a qualitative difference in T cell response (Fig. 3) . Restimulation by antigen presenting cells (APCs) can induce proliferation in responding T cells, which has been documented to occur at the tumor site, in addition to the lymph nodes (30) . It has also been documented that Ki67 has a half life of 60-90 minutes and therefore it is also possible that these cells have been stimulated in the lymph nodes and recently a simplified assay relative to microarray that could be useful in such efforts. We are currently evaluating these ideas by conducting a randomized study of vaccine/Fc-OX40L immunotherapy in pet dogs with naturally occurring glioma.
The high incidence of secondary malignancy in TMZ-treated animals warrants attention.
It is possible that TMZ-exposed T cells are generally more susceptible to transformation in B6 mice, rather than requiring a specific Fc-OX40L/TMZ combination. Further investigation into the effect of TMZ on secondary malignancies in the context of immunotherapy is beyond the scope of this report, but demands caution. We are currently investigating delaying TMZ until after vaccine/Fc-OX40L is completed in dogs with naturally occurring glioma in an attempt to address the theoretical risk of accelerated secondary malignancy by priming TMZ-exposed T cells. The vaccine trials conducted in GBM patients to date have not reported an elevated risk of secondary malignancy, although the caveat is that most treated patients died before meaningful long-term follow up was obtained. As novel immunotherapies are approved that significantly increase patient survival, the risk of secondary malignancy in heavily pretreated patients may become increasingly important. indicates death due to lymphoid neoplasia rather than glioma burden. This experiment was performed once. 
